TrumpRx GLP-1 prices settle around $285 to $349 a month

TrumpRx.gov, the federal drug-purchasing portal built around the Trump administration's Most-Favored-Nation (MFN) pricing framework, is now showing Ozempic at roughly $285 a month and Wegovy at roughly $349 a month as of May 2026, according to a third-party GLP-1 cost-tracking site that monitors the portal ^[1]. Those numbers represent a 68% cut from an approximate $900 retail price for Ozempic and a 74% cut from an approximate $1,350 retail price for Wegovy ^[1].

The portal itself launched on February 5, 2026, backed by an executive order requiring U.S. drug prices to align with the lowest prices paid in other developed nations ^[2]. At launch, the White House said Ozempic's list price would fall from $1,028 to an average of $350 a month, with prices as low as $199 depending on dose, and that Wegovy injections would fall from $1,349 to an average of $350, also as low as $199 depending on dose ^[2]. A Wegovy pill option was listed as low as $149, and Zepbound (tirzepatide) was listed at an average of $346, as low as $299 ^[2].

Those two sets of figures don't line up exactly. The White House's February numbers describe a range with a low end near $199, while the May tracking figures cited above show flat averages of $285 and $349 ^[1][2]. The portal was expanded on May 18, 2026, according to a White House fact sheet referenced alongside the launch materials, which may explain some of the shift, but the sources reviewed do not spell out exactly how pricing tiers changed between February and May ^[2].

According to the May tracking figures, 17 pharmaceutical manufacturers have signed MFN agreements covering 86% of the branded drug market, and GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound are covered ^[1]. Pricing for Mounjaro and Zepbound through TrumpRx was still being finalized as of that report ^[1]. Separately, that source notes Novo Nordisk announced roughly 50% list-price reductions on Wegovy and Ozempic for 2027, though that is a future date and not the same as the current TrumpRx price ^[1].

The claim in the original development that the administration wants injection prices to trend toward $245 over two years does not appear in the two sources reviewed for this article. That specific target is not yet confirmed in the public materials available, so it should be treated as unverified for now.

Why it matters for patients

For patients paying out of pocket, the gap between roughly $285 to $349 a month and retail prices of $900 to $1,350 a month is large enough to change whether a prescription gets filled at all ^[1]. The program appears aimed mainly at people who are uninsured or whose insurance excludes GLP-1 coverage; patients with Medicare, Medicaid, or employer coverage that already pays for these drugs at a low copay may not need or be able to stack TrumpRx pricing on top of existing coverage ^[1].

The price differences between the February launch figures and the May figures matter too. Patients checking TrumpRx.gov should expect prices to vary by dose and possibly by date, and the $199 low-end figure from February is not the same as the $285 figure reported in May ^[1][2]. Anyone comparing options also has other paths to weigh, including manufacturer savings cards, GoodRx pricing (reported around $800 to $850 for Ozempic), and telehealth compounded GLP-1 programs (reported starting around $125 to $299 a month), each with its own eligibility rules and drug formulation ^[1].

What happens next

The TrumpRx portal expanded on May 18, 2026, and the administration has said additional manufacturers and drugs will be added on a rolling basis ^[2]. Novo Nordisk's separately announced roughly 50% list-price cuts on Wegovy and Ozempic are described as taking effect in 2027, which would be a change beyond the current TrumpRx pricing ^[1]. Final pricing for Mounjaro and Zepbound through TrumpRx had not been set as of the May report, and patients were directed to check TrumpRx.gov directly for updates ^[1].